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reduction was more evident in DD patients (placebo DD, 8.4 6Regression of left ventricular hypertrophy by lisinopril after
4.1% vs. lisinopril DD, 27.2 6 5.3, P , 0.05), and a trend wasrenal transplantation: Role of ACE gene polymorphism.
observed in patients with other genotypes (placebo ID/II, 2.8 6Background. Cardiac complications are the main cause of
5.4% vs. lisinopril ID/II, 211.4 6 5%, P 5 0.33).death in renal transplantation (RT), and left ventricular hyper-
Conclusions. Lisinopril decreases LVM in renal transplanttrophy (LVH) may play an important role in these patients. The
patients with hypertension and LVH, and the ACE gene poly-unfavorable genotype of the angiotensin-converting enzyme
morphism may predict the beneficial effect of this therapy.(ACE) gene has been associated with cardiovascular disease,
This finding may be important in targeting prophylactic inter-including LVH. ACE inhibitors (ACEIs) reduce LVH, but little
ventions in this population.is known about the effects of ACEIs on LVH in RT patients
with different insertion/deletion (I/D) genotypes of the ACE gene.
Methods. We prospectively studied 57 stable nondiabetic RT
patients with hypertension and echocardiographic LVH as well
Cardiac complications are the main cause of death inas a functional graft for 69.5 6 5.6 months. Patients randomly
renal transplant patients, and left ventricular hypertro-received either lisinopril 10 mg/day (group A, N 5 29; 5 were
excluded due to reversible acute renal failure) or placebo phy (LVH) is considered a major independent risk factor
(group B, N 5 28) for 12 months. Echocardiography (M-mode, [1–3]. LVH is common in these patients, and some fac-
2-B, and color flow Doppler) was performed at baseline and tors in the process of transplantation, mainly hyperten-6 and 12 months later by the same examiner without previous
sion, have been implicated [4]. In addition, antirejectionknowledge of the genetic typing. The ACE genotype (I or D
therapy (corticosteroids and cyclosporine) could be alsoalleles) was ascertained by polymerase chain reaction (PCR;
group A, DD 5 10 and ID/II 5 14; group B, DD 5 15 and involved in the development of LVH [5, 6].
ID/II 5 13). Several experimental studies have documented the
Results. All patients maintained a good renal function (se-
growth-stimulating and regulating effect of angiotensin IIrum creatinine ,2.5 mg/dL) during the follow-up and both
on myocardial cells [7, 8]. Angiotensin-converting enzymegroups received a similar proportion of antihypertensive drugs
(b-blockers 83 vs. 79%; Ca antagonists 66 vs. 68%; a1-adreno- (ACE) is a key enzyme in the production of this substance,
receptor antagonists 50 vs. 67%) during the study. As expected, and it may therefore participate in the cardiac protein
mean arterial blood pressure and hemoglobin levels showed a synthesis [9]. Conversely, pharmacological inhibition of thehigher percentage reduction in group A versus group B (24 6
angiotensin II synthesis with ACE inhibitors (ACEIs) re-2.8 vs. 2.1 6 2.6%, P 5 0.07, and 211.5 6 1.5 vs. 20.5 6 2.3%,
duced LVH in hypertensive patients more effectively thanP , 0.01, respectively). Group A patients showed a significantly
higher decrement in LV mass index (LVMI) than group B at other antihypertensive drugs [10, 11]. However, this effect
the end of follow-up, after adjusting for age, baseline LVMI, has not been explored after renal transplantation (RT).
time after grafting and changes in systolic blood pressure, renal
An insertion (I)/deletion (D) polymorphism of the ACEfunction, and hemoglobin levels (group A, 29.5 6 3.5% vs.
gene (ACE/ID) has been associated with cardiovasculargroup B, 3 6 3.2%, P , 0.05). As a result, 46% of group A
and only 7% of group B patients showed a reduction of LVMI diseases [12, 13], including LVH [14–16]. In dialysis pa-
$15% (P , 0.01). The beneficial effect of lisinopril on LVMI tients, DD genotype has been associated with a higher
left ventricular mass (LVM) [17]. Recently, we have also
observed that the presence of DD genotype is an inde-Key words: hypertension, cardiovascular disease, acute renal failure,
uremia, angiotensin-converting enzyme gene polymorphism. pendent risk factor favoring LVH in renal transplant
patients [18]. The beneficial response to ACEIs mayReceived for publication June 18, 1999
be influenced by the ACE/ID polymorphism. Individualand in revised form February 11, 2000
Accepted for publication March 14, 2000 differences on the antiproteinuric or renoprotective ef-
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served [19, 20]. The effect of ACEIs on LVM changes Sample size
may be also influenced by this polymorphism of the ACE The planned size was 60 patients, which was based on
gene [21], but this issue has not been explored in renal the assumption of a reduction of at least 15% in LVM
transplant patients. by ACEIs, and less than 3% in the placebo group. With
The present randomized study was undertaken to as- a two-tailed a 5 0.05, the study of 60 patients was expected
sess the long-term effect of an ACEI, lisinopril, on echo- to have 80% power to detect an overall LVM reduction
cardiographic, morphological and functional changes in of 15%, based on an intention-to-treat analysis.
hypertensive renal transplant patients with LVH, whose
ACE genotype was also determined. Study objectives
The primary objective was to investigate the effect of
treatment with lisinopril on the rate of change in LVM inMETHODS
stable hypertensive renal transplant patients with LVH.The study was performed in a single-dose, single-blind,
A secondary objective was to assess the influence ofrandomized, placebo-controlled design during 12 months.
the ACE/ID polymorphism on the cardiac changes in-
duced by lisinopril. In addition, adverse events, renalPatients
function, and blood pressure response were also regu-Study participants were stable nondiabetic, long-term
larly recorded in each group.renal transplant patients of both sexes (25 to 70 years
old) with arterial hypertension and echocardiographic Study design
evidence of LVH. Inclusion criteria were the following:
After screening assessment, all eligible patients en-(1) presence of hypertension, defined as a systolic and
tered a one-month single-blind, placebo run-in phase. Atdiastolic blood pressure .150/90 mm Hg, requiring two
the end of this period, patients with capsule complianceor more antihypertensive drugs for adequate blood pres-
exceeding 80% were enrolled in the study. Patients weresure control; (2) no previous treatment with ACE inhibi-
randomly assigned to receive either 10 mg/day of lisino-tors or angiotensin II receptor antagonists; (3) stable
pril (group A, N 5 29) or placebo (group B, N 5 28)renal function, with a serum creatinine level ,2.5 mg/dL
for 12 months. Because lisinopril provides relatively con-or ,221 mmol/L for more than six months; (4) presence
stant plasma concentration of the drug over 24 hoursof LVH, assessed by echocardiographic criteria; (5) ab-
[23], patients were instructed to take the medication atsence of clinical features of heart failure or significant
a convenient but consistent time of the day to ensurevalvular disease; (6) absence of renal artery stenosis or
compliance. All of the tablets had identical appearancechronic allograft nephropathy; (7) no documentation or
and were provided by Vita S.A. (Barcelona, Spain).clinical suspicion of renovascular hypertension; and (8)
Clinical and biochemical data were measured at theabsence of proteinuria.
randomization visit and every three months thereafter.Exclusion criteria during follow-up were: (1) incre-
Initially, evaluation of renal function was performedment of serum creatinine level by 20% or more during
twice weekly. Lisinopril was discontinued if plasma cre-treatment, (2) severe side effects, (3) detection of chronic
atinine had increased by $20% during this period. Thisallograft nephropathy, and (4) pregnancy.
cut-off value was based on previous studies in which aWomen were advised about physical anticonceptive
minimum increase in plasma creatinine during ACEImeasures during follow-up.
treatment of $20% was considered significant [24]. OnIn all patients, immunosuppression consisted of anti-
the other hand, if plasma creatinine had not changed orthymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI,
increased less than 20%, lisinopril was continued duringUSA) for induction, and prednisone, cyclosporine, and
follow-up.azathioprine for maintenance. Recipients older than 50
The goal of antihypertensive therapy was to obtain ayears did not receive azathioprine. Episodes of acute
blood pressure #145/90 mm Hg in both groups during therejection were initially treated with three boluses of 500
study. Thus, antihypertensive agents, other than ACEIsmg of intravenous methylprednisolone. Resistant epi-
or angiotensin II receptor antagonists, were adjusted tosodes were treated with a 10-day course of OKT3 (5 mg/
achieve this blood pressure control during follow-up asday). Cyclosporine was adjusted according to the total
in standard clinical practice.blood levels [22].
Echocardiographic parameters were measured at base-The study was approved by the Ethics Committee of
line and at 6 and 12 months later.the Hospital Universitario and by the Direccio´n General
All patients were asked about adverse events at eachde Farmacia (Spanish Ministry of Health, Madrid, Spain).
visit. Serious adverse events were defined as withdrawalThis study was conducted according to the Declaration
for any serious medical reason, death, any major morbidof Helsinki, and each patient gave written informed con-
sent to participate in the study. event or hospital admission for any reason, and any ab-
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normal laboratory value associated with signs or symp- The mean of measurements from three to five consecu-
tive cardiac cycles was determined for each of these indices.toms or requiring treatment. Withdrawal from treatment
could result from a serious adverse event or from the
Genomic typing of the ACE deletion/patient’s wishes.
insertion polymorphism
Laboratory measurements The previously described D and I alleles of the ACE
gene were ascertained by polymerase chain reaction (PCR)Serum creatinine and other biochemical parameters
(uric acid, glucose, and complete blood count) were mea- amplification of a fragment of intron 16 of the ACE gene
[29]. DNA was purified from 3 mL of blood by proteinasesured by means of a computerized autoanalyzer (Hitachi
717; Boehringer Mannheim, Mannheim, Germany). To- K digestion, phenol extraction, and ethanol precipitation,
following standard protocols [30]. Approximately 0.1 mgtal blood cyclosporine levels were quantitated by fluo-
rescence polarization immunoassay (FPIA) using a mono- DNA was amplified with primers hace3s, 59-GCCCTGC
AGGTGTCTGCAGCATGT-39, and hace3as, 59-GGAclonal antibody (Abbot, IL, USA).
TGGCTCTCCCCGCCTTGTCTC-39, which yield PCR
Echocardiographic technique and data collection products of 319 bp and 597 bp for the D and I alleles,
respectively. PCR conditions included 10 mmol/L Tris-M-mode, two-dimensional, and color-flow Doppler
echocardiograms were performed by the same examiner HCl, pH 9.0, 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.1%
Triton X-100, 0.1 mmol/L dNTPs, 0.5 mmol/L each(J.L.) without previous knowledge of the genetic typing,
clinical characteristics, and study group, both at baseline primer, and 1 U Taq DNA polymerase. A Perkin-Elmer
480 thermal cycler was used to carry out 30 amplificationand after follow-up. Each echocardiographic tracing was
coded and interpreted at random by a second experienced cycles with the following temperature profile: 948C
(1 min), 628C (1 min), and 728C (1 min). Ten microlitersobserver (A.B.), who was also unaware of the subjects’
identity, clinical characteristics, and treatment group. In of the amplification product were resolved by electro-
phoresis in 5% polyacrylamide gels and visualized underour laboratory, interobserver variability for these mea-
surements in 10 repeated studies averaged ,10% [18]. ultraviolet light after staining with 0.5 mg/mL ethidium
bromide.Echocardiograms were obtained with the patient in the
left decubitus position with 308 head inclination, using All samples yielding exclusive amplification of the D
allele (and therefore potentially typed as DD) were sub-an ultrasonoscope (Aloka SSZ-203) with either a 2.5 or a
3.5 MHz transducer. The left ventricular echocardiogram jected to a second independent amplification, as described
by Lindpaintner et al [29]. Briefly, samples were amplifiedwas recorded following a standard protocol at or just
below the tips of the mitral valve leaflets, with the trans- under the same buffer conditions as described previously
in this article, except for the use of primers specific for theducer applied to the third or fourth intercostal space.
Measurements of cavities and cardiac walls were under- sequence inserted in intron 16 of the I allele, and a temper-
ature profile of 948C, 678C, and 728C for one minutetaken following the recommendations of the American
Society for Echocardiography [25]. LVM was determined each. The primer sequences are hace5a, 59-TGGGACC
ACAGCGCCCGCCACTAC-39, and hace5c, 59-TCGCaccording to the method of Devereux and Reichek [26]
and indexed to body surface area to yield the LVM index CAGCCCTCCCATGCCCATAA-39, which result in an
amplification product of 335 bp only in the presence of(LVMI). The cut-off level defining LVH was a LVMI .
143 g/m2 in men and LVMI . 102 g/m2 in women [27]. an I allele.
Using the same procedure, we also estimated the alleleLeft ventricular systolic function was assessed by the ejec-
tion fraction, which was calculated as LVEDV-LVESV/ frequencies for the I/D polymorphism at the ACE locus
among 246 DNA samples from healthy individuals andLVEDV where LVEDV and LVESV are end-diastolic
and end-systolic volumes both calculated by the formula among 248 unselected DNA samples from renal transplant
patients.of Teichholz et al [28]. The Doppler echocardiography
was performed immediately after the M-mode examina-
Statistical analysistion. Transmitral flow velocity signals were recorded si-
multaneously with an electrocardiogram and a phono- Friedman two-way analysis of variance (ANOVA) by
rank test was used to compare repeated echocardiographiccardiogram. The following measurements were obtained:
maximal early (peak E) and late (peak A) diastolic flow measurements during the study. Intragroup pair-wise
comparisons were performed by the Wilcoxon signed-velocities in centimeters per second, deceleration time of
flow velocity in early diastole (DT), and left ventricular rank test with adjusted degrees of freedom. The general
factorial analysis of variance (ANCOVA) was used toisovolumic relaxation time (LVIRT) in milliseconds. In
addition, the ratio of peak flow velocity in early diastole measure the treatment effect on the rate of change of
different biological variables, after adjusting for otherto peak flow velocity during atrial systole (E/A) was
calculated. potential confounding covariables. For univariate com-
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Table 1. Demographic, clinical and immunosuppression data atparison of numerical variables, U-Mann–Whitney was
baseline, and 6 and 12 months after treatment in both groups
used. All categorical variables were analyzed using chi-
Group A: Group B:square test or Fisher’s exact probability test (two tailed)
Lisinopril Placeboas appropriate. N 5 24 N 5 28
Results are expressed as mean 6 SE. A P value less
Age years 46.962.6 50.262.5
than 0.05 was considered significant. All computations Sex M/F 16/8 18/10
Time after renal transplantwere made using the SPSS 7.5 statistical package for
months 56.563.8a 7765.6Windowst (Chicago, IL, USA). Genetic statistics were
Antihypertensive drugs %
performed with Genepop v.3.1. b-blockers 83% 79%
Ca antagonists 66% 68%
a1-adrenoreceptor antagonists 50% 67%
Systolic blood pressure mm HgRESULTS
Baseline 147.664.3 147.962.8
Of the 57 patients who were recruited, 5 patients of 6 months 145.564 153.662.9
12 months 140.663.9b 150.763.7the lisinopril group initially withdrew from the study for
Diastolic blood pressure mm Hgreversible acute renal failure (increment of level serum
Baseline 90.663.3 89.762.5
creatinine $20% during the first week). Thus, 24 patients 6 months 88.762.9 89.661.8
12 months 85.462.2 90.762.3were assigned to receive lisinopril and 28 to receive pla-
Mean arterial pressure mm Hgcebo, and all of them completed the study. No drug-
Baseline 109.663.3 109.162.1
related side effects were observed in this cohort complet- 6 months 107.762.9 110.961.6
12 months 103.862.5b 110.762.4ing the study, and no patients suffered cardiac failure or
Mean arterial pressure change %angina pectoris during follow-up. Table 1 summarizes
12 months after treatment 2462.8c 2.162.6
clinical, immunosuppression, and renal function data by Cumulative steroids g 19.761.1 21.661.4
CsA levels ng/mLtreatment groups at baseline and at 6 and 12 months
Baseline 215610.3 235.8610.3later. A longer time after grafting was observed in pa-
6 months 222.669.6 215.268.9
tients receiving placebo. Both groups received a similar 12 months 19567.4 205.767.4
Body mass index kg/m2proportion of other antihypertensive drugs during the
Baseline 28.461.07 28.460.6study. Moreover, systolic, diastolic, and mean arterial
6 months 28.161 28.860.7
pressure were not different at baseline. However, there 12 months 2861 28.660.7
Serum creatinine mg/dLwas a trend to lower values in mean arterial pressure at
Baseline 1.4860.07 1.560.08the end of follow-up in the lisinopril group (Table 1).
6 months 1.4960.07 1.3460.07
As expected, a greater reduction of hemoglobin levels 12 months 1.560.06 1.460.08
Hemoglobin levels g/dLwas observed in the lisinopril group. Other clinical data
Baseline 14.160.3 13.860.3such as renal function, antirejection therapy, and body
6 months 12.860.27a 14.260.3
mass index were similar in both groups. 12 months 12.460.32a 13.760.3
Hemoglobin level change % 211.561.5a 20.562.3Morphological echocardiographic data from both groups
ACE genotypeare summarized in Table 2. Patients receiving lisinopril
number of patients 10 DD, 13 ID, 15 DD, 12 ID,
showed a significant decrease in LVMI at end of follow- 1 II 1 II
up, as compared with the placebo group (unadjusted Conversion factors to SI units: Creatinine 88.4 (mmol/L).
a P , 0.01, bP 5 0.05, cP 5 0.07 vs. Placebo groupdata), and the highest specific reduction was, on average,
for the posterior wall (Table 2). However, a trend toward
higher baseline LVMI was observed in the lisinopril
group. Thus, a general factorial analysis was applied us- All samples typed as DD with the first assay (primer
ing LVMI as the dependent variable, and treatment (pla- hace3s and hace3as) were confirmed to lack the I allele
cebo or lisinopril) as factor, while adjusting for age, base- by using the second assay (primers hace5a and hace5c),
line LVMI, time after grafting, and changes in systolic and no disagreement was found between both assays.
blood pressure, renal function, and hemoglobin levels. The distribution of the DD, ID, and II genotypes in our
Interestingly, the mean adjusted decrease in LVMI was patients was 48.1% (N 5 25), 48.1% (N 5 25), and 3.8%
again significantly greater in the lisinopril group. As a (N 5 2), respectively, with estimated allele frequencies
result, 46% of patients receiving lisinopril and only 7% of 72.1% (D) and 27.9% (I). For the 246 samples from
of patients on placebo showed regression of LV mass healthy individuals, the following frequencies were ob-
$15% (P , 0.01; Table 2). Other echocardiographic tained: 37.8% DD, 49.2% ID, 13% II, with estimated
parameters were similar in both groups during the study. allele frequencies of 62.4% (D) and 37.6% (I). Among
Table 3 shows Doppler echocardiographic data during the 248 unselected transplant recipients, 39.5% were
follow-up. Overall diastolic function was similar in both DD, 50.4% ID, 10.1% II, with estimated allele frequen-
cies of 64.7% (D) and 35.3% (I). Genotype frequenciesgroups during the study.
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Table 3. Doppler echocardiographic measurements at baseline, andTable 2. Echocardiographic parameters at baseline, and 6 and 12
months after treatment in both groups at 6 and 12 months after treatment
Group A: Lisinopril Group B: PlaceboGroup A: Lisinopril Group B: Placebo
N 5 24 N 5 28 N 5 24 N 5 28
Peak E cm/sLVESD mm
Baseline 2860.8 2961.4 Baseline 73.164 69.364
6 months 78.564 75.8646 months 29.360.8 27.961.1
12 months 28.161.2 27.461.2 12 months 74.764.3 71.463.6
Peak A cm/sLVEDD mm
Baseline 50.161 48.761.3 Baseline 6563 71.464
6 months 7264 73.8636 months 5260.9 50.361.2
12 months 5160.9 49.861.3 12 months 6963.8 7664
E/A ratioLAD mm
Baseline 39.761.2 39.861 Baseline 1.1760.9 1.0260.8
6 months 1.1560.9 1.0660.76 months 4161.3 41.160.9
12 months 3961.6 39.860.9 12 months 1.1460.9 1.0160.8
DT msLVEF %
Baseline 7261.5 70.561.9 Baseline 236611.5 241.8613.6
6 months 215.3610 232611.76 months 70.861.4 70.262
12 months 70.862 7061.8 12 months 236.6613.8 235617.2
LVIRT msIVST mm
Baseline 13.760.5 13.160.4 Baseline 103.169.4 99.367
6 months 10169.7 98.966.56 months 1360.6 12.660.5
12 months 12.660.5 12.960.5 12 months 96.466.6 98.666.4
PWT mm Abbreviations are: Peak E, peak of early diastolic flow velocity; peak A, peak
Baseline 12.660.4 12.360.3 of late diastolic flow velocity; E/A ratio, ratio of early to late diastolic flow; DT,
6 months 11.960.4 12.160.4 deceleration time of E wave; LVIRT, left ventricular isovolumetric relaxation
12 months 11.260.5 12.160.3 time.
LVMI g/m2
Baseline 176.467.6c 160.567.3
6 months 174.368.7 160.366
12 months 157.867.9d 164.167.6
LVMI change % tients with DD genotype receiving lisinopril showed a
6 months 0.264.4 1.6863.9 significant reduction of LVMI as compared with DD pa-
12 months
tients on placebo, after adjusting for age, baseline LVMI,unadjusted 29.263.8a 2.862.3
adjusted 29.563.5b 363.2 time after grafting, and changes in systolic blood pres-
Patients with regression sure, renal function and hemoglobin levels (27.2 6 5.3
of LV mass $15% at
vs. 8.4 6 4.1%, P , 0.05). This effect could be due to a12 months % 11 (46)a 2 (7)
trend toward an increase of LVMI in DD patients onAbbreviations are: LVESD, left ventricular end-systolic diameter; LVEDD,
left ventricular end-diastolic diameter; LAD, left auricular diameter; LVEF, placebo at the end follow-up. The clinical consequence
left ventricular ejection fraction; IVST, interventricular septal thickness; PWT, of the lisinopril effect on DD patients was a higher pro-posterior wall thickness; LVMI, left ventricular mass index; LVH, left ventricular
hypertrophy. Data of LVMI changes at 12 months are presented in unadjusted portion of patients showing a reduction of LV mass $15%
form and when adjusted for age, baseline LVMI, time after grafting, and changes as compared with placebo (40 vs. 6.6%, P 5 0.05). Like-in systolic blood pressure, renal function and hemoglobin levels.
a P , 0.01, b P , 0.05, c P , 0.1 vs. Placebo group wise, DD patients receiving lisinopril also showed a trend
d P , 0.05 vs. Baseline
toward a lower isovolumetric relaxation time at end of
follow-up than those on placebo, after adjusting for the
previously mentioned confounding variables (Table 4).
On the other hand, ID/II patients under lisinopril alsowere not significantly different (chi-square 4.76, P 5 0.31)
showed a trend toward a greater reduction of LVMIamong the various groups studied. Genotype frequencies
of both study groups, the healthy group and the unse- than those on placebo (Table 4).
lected transplanted patients, were not significantly differ- Interestingly, the beneficial effect of lisinopril in the
ent from the predictions of the Hardy–Weinberg model DD group as compared with ID/II could not be due to
(HW exact probability test, P 5 0.30, P 5 0.50, and P 5 a better control of blood pressure (mean blood pressure
0.13, respectively). reduction DD, 26.6 6 4.6 vs. ID/II, 22 6 3.5, P 5 NS).
Several reports have demonstrated that DD patients
have both higher angiotensin II levels and greater LVM
DISCUSSIONthan other genotypes [14–17]. Thus, we analyzed the
We demonstrated that a one-year treatment with lisi-effect of treatment in DD patients and in those with
nopril significantly decreased LVM in hypertensive renalother genotype (ID/II) as a group, as has been performed
transplant patients with LVH, and the highest changein other studies [17, 31]. Table 4 shows clinical and echo-
was for the posterior wall thickness. Moreover, the bene-cardiographic data of the two treatment groups (placebo
or lisinopril) in DD and ID/II patients separately. Pa- ficial effect of lisinopril was independent of other factors
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Table 4. Clinical and echocardiographic data in patients with different genotypes at baseline, 6 and 12 months after treatment
DD Patients (N 5 25) ID and II Patients (N 5 27)
Placebo Lisinopril Placebo Lisinopril
N 5 15 N 5 10 N 5 13 N 5 14
Age years 49.663.9 48.564.5 5163 4663.2
Sex M/F 10/5 6/4 8/5 10/4
Time after grafting months 73.568.2 67.5611.6 8167.8 5663.8c
Systolic BP
Baseline 147.364.7 149.569.7 148.562.8 146.363.2
6 months 152.564.2 14764 15464 144.566.5
12 months 153.365.3 136.167d 147.864.6 143.864.6
Diastolic BP
Baseline 91.563.4 85.866 87.663.7 9463.6
6 months 89.6861.8 8464.5 89.663.3 92.263.8
12 months 89.463.4 78.263.4b 92.163.4 90.562.6
MAP mm Hg
Baseline 11063 10766.9 10862.8 111.463.2
6 months 110.661.5 10563.5 111.363 109.664.4
12 months 110.763.4 97.563.5a 110.663.5 108.363
MAP change % 12 months 1.363.7 26.664.6 3.263.9 2263.5c
Serum creatinine mg/dL
Baseline 1.560.1 1.4860.1 1.560.1 1.4760.9
6 months 1.2760.9 1.4560.1 1.4360.1 1.560.1
12 months 1.3660.1 1.3460.8 1.4760.1 1.560.9
Hemoglobin levels
change % 12 months 0.760.4 211.661.5a 2262 211.562.3
LVMI g/m2
Baseline 15768.6 168613 164.5612.5 182.469.4
6 months 15466.6 177.8612.4 168.3610.5 172.3612
12 months 168.269.4 154.7612.6 159.4612.6 16068
LVMI change % 12 months
unadjusted 7.863.2 26.266b 22.862.6 211.465
adjusted 8.464 27.265.3b 22.865.4 211.465
LVIRT ms
Baseline 102.2611 109.2621 9668.4 99.268
6 months 112.369.7 121623 83.466.4 89.666
12 months 10667.7 81.2611.2d 90.168.5 105.867.5
LVIRT change % 12 months
unadjusted 11.5610 214.4612d 23.268 866
adjusted 16.5611.4 223617.3d 23.669 8.468.2
Abbreviations are: BP, blood pressure; MAP, mean arterial pressure; LVMI, left ventricular mass index; LVIRT, left ventricular isovolumetric relaxation time.
Data of LVMI and LVIRT changes are shown in unadjusted form and when adjusted for age, baseline LVMI and LVIRT, time after grafting, and changes in
systolic blood pressure, renal function and hemoglobin levels.
DD patients: Lisinopril vs. Placebo: aP 5 0.02; bP , 0.05; dP , 0.1
ID/II patients: Lisinopril vs. Placebo: cP , 0.01
known to affect LVM such as age, blood pressure, base- demonstrated in the general population [3]. Thus, a re-
duction of LVM indeed emerges as a desirable goal inline LVM, time after grafting, renal function, and hemo-
globin levels. In addition, the beneficial effect of lisinopril renal transplant patients. Since ACEIs may induce acute
renal failure even without renal artery stenosis [24, 33],was more evident in DD patients. In order to minimize
coexistent abnormalities, we only included nondiabetic this controlled study was performed in a single-blind
design. The increase in serum creatinine has been relatedpatients with an acceptable renal function. We used 10
mg/day of lisinopril, which is the minimal reported dose to changes in the glomerular hemodynamics, with a tran-
sient decrease in glomerular filtration rate.that reduces LVM in hypertensive patients [32]. No drug-
related side effects were observed in the cohort complet- As expected, a greater reduction in hemoglobin levels
was observed in patients receiving lisinopril, but it had noing the study, although five patients were excluded in
the initial evaluation as a consequence of renal function clinical significance. This side effect is very common with
the use of ACEIs [34] and may have a deleterious effectimpairment. To our knowledge, this is the first random-
ized placebo-controlled study to investigate the efficacy on LVMI [35]. However, a higher reduction of LVM was
observed in this group, suggesting that blockade of localof lisinopril on LVM in renal transplant patients with
hypertension and LVH. This condition may be a major angiotensin II by lisinopril was more important than the
effect on hemoglobin levels.cardiovascular risk factor in these patients, as has been
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Both groups received a similar proportion of antihyper- observed in our previous studies [18]. Thus, the beneficial
tensive drugs other than lisinopril during the follow-up. effect of the ACEIs may be under genetic influence. We
Although blood pressure was well controlled during the analyzed individual evolution of LVM in patients with
study, patients receiving lisinopril showed a trend toward different genotypes after treatment with lisinopril. DD
a greater reduction of blood pressure at the end of the patients receiving lisinopril showed a significant reduc-
study. Thus, this effect may have contributed to the bene- tion of LVM as compared with patients on placebo, after
ficial effect of lisinopril on LVMI. However, after ad- adjusting for other confounder covariates. Patients with
justing for blood pressure changes, lisinopril induced a ID or II genotype also showed a higher decrease of
significant reduction of LVMI, which was not observed LVMI as compared with those with placebo, although a
in the placebo group. In addition, no correlation between greater sample size may be needed to reach statistical
LVM and blood pressure changes during the study was significance. Finally, DD patients on lisinopril showed a
observed (data not shown). This finding is in agreement trend to lower isovolumetric relaxation time at the end
with previous observations both in hypertensive and nor- of follow-up as compared with DD patients on placebo.
motensive humans, showing that the ACEIs are able Similar to our findings, Sasaki et al observed that
to induce regression of LVM by mechanisms that are changes in LVMI and diastolic function were significantly
independent of blood pressure changes [36, 37]. greater in DD hypertensive patients receiving enalapril
Previous studies have clearly demonstrated that angio- [21]. Other authors have also shown a greater antipro-
tensin II participates in the development of myocardial teinuric effect of ACEIs in renal patients with the DD
hypertrophy, regardless of changes in arterial pressure genotype, suggesting a more intensive vasodilatation ef-
and cardiac workload [11, 38]. ACEIs may antagonize fect in this group [19, 42]. As a higher availability of local
the growth-promoting influence of angiotensin II, and angiotensin II in DD patients would be expected, the
the local blockade of this system may be more important antiproliferative and vasodilator effect of ACEIs might
than the circulating one. Indeed, ACEIs, given in very be more prominent in renal transplant patients with DD
low doses that do not affect blood pressure, prevented genotype, thus inducing a greater reduction of LVM.
the development of cardiac hypertrophy in pressure- In contrast to our study, a major beneficial effect of
overloaded rats [39]. Another possible mechanism is that ACEIs has not been found in uremic or diabetic patients
blockade of local angiotensin II by lisinopril increases with DD genotype [31, 43, 44]. It is possible that other
aortic compliance, leading to LVH reversal, as has been factors like volume overload, anemia, endocrine disor-
recently demonstrated in hypertensive patients [36]. Fi- ders, or high parathyroid hormone levels present in these
nally, blockade of the renin-angiotensin system could patients may obscure differences between genotypes. In
also improve sympathovagal imbalance, modulating the
addition, ethnic heterogeneity may play an important
reactivity and release of cathecolamines, which could
role in the response to ACEIs in patients with differenthave trophic influences on myocardial growth [40].
genotypes of the ACE gene. A recent meta-analysis,In this study, overall diastolic function was similar in
showing different evolution of diabetic nephropathy be-both groups during follow-up, and the E/A ratio did
tween Caucasian and Asian DD patients, supports thisnot change. London et al were also unable to observe
hypothesis [45].changes in diastolic function after treatment with ACEIs
Cyclosporine clearly stimulates both circulating andfor one year in uremic patients [37]. It is possible that a
local renin-angiotensin systems, as evidenced by its acti-longer period of treatment and/or a greater reduction in
vation of different components of this system in multipleLVM are needed to induce significant changes in dia-
tissues [46]. An activated renin-angiotensin system maystolic function. This is supported by recent data demon-
help to separate better the consequences of the ACE poly-strating that the improvement of diastolic function with
morphism in renal transplant patients. In other words,ACEIs was related to reduction in ventricular mass and
the ACE DD genotype may have a permissive role innot to a decrease in mean arterial pressure or improve-
the development of LVH when the cardiac growth ma-ment in aortic compliance [36, 41].
chinery is stimulated. Therefore, a more pronouncedAn I/D polymorphism of the ACE gene has been
effect of ACEIs on LVM regression might be expectedshown to be a genetic factor influencing both circulating
in DD transplant patients.and tissue ACE levels. ACE activity is higher in DD
In conclusion, lisinopril decreases LVM in renal trans-patients than other genotypes, and these subjects have
plant patients with hypertension and LVH, regardlessa greater cardiovascular risk [13]. In fact, in our DD
of other clinical data that interact on ventricular mass.patients receiving placebo for one year, LVMI showed
In addition, the I/D ACE genotype may predict the ex-a mean increase of 8.4%, which contrasts with a 2.8%
tent to which LVM will be lowered by lisinopril. Thisdecrease in ID/II patients on placebo (these differences
effect may be important in targeting prophylactic inter-did not reach statistical significance possibly as a conse-
quence of the sample size). A similar effect had been ventions in these patients.
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